Biologics: The Growth Engine In Advanced Wound Care
With estimated revenues in excess of $5 billion per year worldwide, the advanced wound care market has garnered the attention of both major companies and investors for its tremendous potential. Growth in this market is being driven by the development of new bioactive products that can successfully heal chronic wounds such as diabetic foot ulcers, which are among the most challenging and costly to treat. This article is reprinted from the June issue of Medtech Insight.
You may also be interested in...
Bayer’s aflibercept, Leo’s ingenol mebutate, Almirall’s linaclotide and a proteolytic enzyme concentrate, Teva’s NexoBrid, were given positive opinions on their marketing by CHMP on Sept. 21, with Almirall taking a different approach to linaclotide’s development than that taken in the U.S.
Dermagraft is often mentioned as an example of a failure in tissue engineering, illustrating the difficulty of achieving return on investment in this field. The product was only a market failure, however; clinicians say that it worked to heal difficult wounds, and that it was just a product ahead of its time. Now small company Advanced BioHealing has given new life to the bioengineered dermal substitute, abandoned by Smith & Nephew, by supporting it with the focus, and the unique marketing and manufacturing skills that tissue-engineered products require. In the process, it believes it has created assets and skill-sets from which other tissue-engineering start-ups might benefit.
Deal Snapshot: Other major players have made headway in bispecifics for prostate cancer, while Jemincare’s drug is the latest China-developed technology to head westward.